此外，HER2 阳性 CRC 患者在接受标准化疗（如 FOLFOX 方案）时，通常反应较差，显示出对抗 EGFR 疗法的耐药性 [6] 。因此，HER2 的检测在 CRC 的治疗 ...

The recent approval of the dual-inhibitors (EGFR/HER2), such as lapatinib, opens a new avenue for therapeutic strategies with multitargeted drugs, not only directed against the surface receptors ...

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

在最新的destiny-lung05Ⅱ期临床试验研究数据显示，对于经治的her2突变非小细胞肺癌患者，德曲妥珠单抗的客观缓解率（orr）达到了58.3%，中位无进展 ...

“While S1613 showed that anti-HER2 therapy was better tolerated and similarly efficacious to anti-EGFR therapy, the key finding is that the relative benefit of these therapies may depend on the ...

BMBC is particularly common in breast cancers that are positive for epidermal growth factor receptor1 and 2 (EGFR and HER2), however, targeted therapies against BMBC, e.g., lapatinib - a EGFR/HER2 ...